Pharmaceuticals company Jubilant Pharmova announced Q1FY25 results: Total income in Q1FY25 grew by 9% YoY to Rs 1,746 crore, driven by growth in Ruby-Fill and new product sales in radiopharmaceuticals, volume growth in radiopharmacies, and continued momentum in the Allergy Immunotherapy and CDMO Sterile Injectables businesses. EBITDA increased by 50% YoY to Rs 266 crore due to improved performance across all segments: Radiopharma, Allergy Immunotherapy, CDMO Sterile Injectables, CRDMO, and Generics. PAT for Q1FY25 stood at Rs 482 crore normalized PAT saw a significant increase of 1,055% YoY to Rs 69 crore driven by enhanced operating performance. In June 2024, the company received stake sale proceeds of up to USD 115.9 million from Sofie Biosciences Inc., leading to a voluntary debt repayment of USD 75 million (Rs 626 crore). As a result, net debt reduced from Rs 2,509 crore in March 2024 to Rs 1,869 crore. Net debt/EBITDA ratio also improved from 2.5x to 1.7x compared to March 2024. Result PDF
Pharmaceuticals company Jubilant Pharmova announced Q4FY24 & FY24 results: Q4FY24 Financial Highlights: Total income: Rs 1,773 crore (5% increase compared to Q4FY23) Reported EBITDA: Rs 289 crore (20% increase compared to Q4FY23) EBITDA margin: 16.3% (Increased by 200 basis points compared to Q4FY23) Normalized PAT: Rs 61 crore (122% decrease compared to Q4FY23) FY24 Financial Highlights: Total income: Rs 6,772 crore (7% increase compared to FY23) Reported EBITDA: Rs 994 crore (20% increase compared to FY23) EBITDA margin: 14.7% (Increased by 160 basis points compared to FY23) Normalized PAT: Rs 195 crore (63% increase compared to FY23) The Board of Jubilant Pharmova Limited met today to approve financial result for the quarter and financial year ended Mar 31, 2024. The board has proposed a dividend of Rs 5 per equity share. Result PDF